## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.9% in lower entry zone (3.0-6.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (2.7%) confirms momentum alignment. Strong momentum (+2.8% 5-day acceleration). Outperforming sector by 6.2%. Caution: overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($49.55)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Dodge & Cox Has $390.54 Million Stake in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251205T100731 | Neutral | Relevance: 99%
-  Dodge & Cox reduced its stake in Bristol Myers Squibb Company by 35.3% in the second quarter, now owning 8.4 million shares worth $390.54 million. Other hedge funds also adjusted their holdings, with institutional investors owning 76.41% of the company's stock. Bristol Myers Squibb recently reported strong quarterly earnings and a dividend announcement, while analysts maintain a "Hold" consensus rating with an average target price of $55.25.

**2. Bristol Myers Squibb stock rises after continuing Phase 3 Alzheimer’s study**
- Source: Investing.com Nigeria | 20251203T131600 | Bullish | Relevance: 99%
- Bristol Myers Squibb stock rose 1.5% after the company announced its decision to continue its ADEPT-2 Phase 3 study for psychosis associated with Alzheimer’s disease. The company excluded data from certain sites due to irregularities but maintained the study's integrity, seeking FDA consultation and independent analysis. New patient enrollment will proceed to meet the original target population, with results expected by the end of 2026 for the drug Cobenfy.

**3. Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease**
- Source: BioSpace | 20251203T144557 | Somewhat-Bullish | Relevance: 99%
- Bristol Myers Squibb announced the continuation of its ADEPT-2 Phase 3 study for psychosis associated with Alzheimer's Disease, following the recommendation of an independent Data Monitoring Committee. The company is enrolling additional patients after excluding data from a small number of sites due to execution irregularities, demonstrating its commitment to study integrity. This decision, made in consultation with the FDA, aims to identify innovative treatment options for this significant unmet medical need.

**4. Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)**
- Source: Bristol Myers Squibb | 20251205T012203 | Bullish | Relevance: 99%
-  The U.S. FDA has approved Bristol Myers Squibb's Breyanzi® (lisocabtagene maraleucel; liso-cel) as the first and only CAR T cell therapy for adult patients with relapsed or refractory marginal zone lymphoma (MZL) after at least two prior systemic therapies. This approval, based on the TRANSCEND FL study, demonstrated an overall response rate of 95.5% and a complete response rate of 62.1% in the MZL cohort, with a consistent safety profile. Breyanzi is now approved for five cancer types, solidifying its position as a leading CD19-directed CAR T cell therapy.

**5. A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.**
- Source: MarketWatch | 20251203T190500 | Somewhat-Bullish | Relevance: 98%
- Bristol Myers Squibb's stock rose by about 6% after the company announced a delay in the readout of a key Phase 3 clinical trial for its drug Cobenfy, intended for Alzheimer’s disease psychosis. The delay is due to the need to enroll more patients, pushing the data release to sometime next year instead of end-2025. This unexpected positive market reaction suggests investors may have factored in potential risks or are optimistic about the drug's eventual success.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (2 raises, avg +15%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.1B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.7 |
| Current P/E | 8.0 |
| YoY Growth | -8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.1% to 3.9% (+2.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 2.7% confirms short-term momentum alignment. Outperforming sector by 6.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.89% (CS: 87) | Strong |
| RSI_14 | 71.9 | Overbought |
| MACD Histogram | 0.41 | Bullish |
| vs SMA20 | 1.079x | Above |
| vs SMA50 | 1.131x | Above |
| vs SMA200 | 1.062x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $52.15
- **Stop Loss:** $49.55 (5.0% risk)
- **Target:** $56.05 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 192
- **Position Value:** $10,012.80
- **Portfolio %:** 10.01%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*